{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:56:20Z","timestamp":1791964580592,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10557-025-07736-8","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:55:13Z","timestamp":1750395313000},"page":"697-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct Oral Anticoagulants in Valvular Diseases and Prosthetic Valves: Why Not?"],"prefix":"10.1007","volume":"40","author":[{"given":"Konstantinos","family":"Lampropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6121-2479","authenticated-orcid":false,"given":"Michail","family":"Penteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Gerotziafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"7736_CR1","unstructured":"Libby, Bhatt, Bonow et al. Braunwald\u2019s heart disease. 12th ed. Elsevier Saunders; 2021."},{"key":"7736_CR2","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. GBD-NHLBI-JACC global burden of cardiovascular diseases writing group. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010. Erratum. In: J Am Coll Cardiol. 2021 Apr 20;77(15):1958\u20131959. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.039.","DOI":"10.1016\/j.jacc.2020.11.010"},{"issue":"10 Pt 2","key":"7736_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1111\/j.1540-8159.1997.tb06115.x","volume":"20","author":"S L\u00e9vy","year":"1997","unstructured":"L\u00e9vy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20(10 Pt 2):2670\u20134. https:\/\/doi.org\/10.1111\/j.1540-8159.1997.tb06115.x.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"1","key":"7736_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/ijms23010006","volume":"23","author":"M Sagris","year":"2021","unstructured":"Sagris M, Vardas EP, Theofilis P, et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23(1):6. https:\/\/doi.org\/10.3390\/ijms23010006.","journal-title":"Int J Mol Sci"},{"issue":"74","key":"7736_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-med-042921-122533","volume":"27","author":"MF Eleid","year":"2023","unstructured":"Eleid MF, Nkomo VT, Pislaru SV, Gersh BJ. Valvular heart disease: new concepts in pathophysiology and therapeutic approaches. Annu Rev Med. 2023;27(74):155\u201370. https:\/\/doi.org\/10.1146\/annurev-med-042921-122533.","journal-title":"Annu Rev Med"},{"issue":"19","key":"7736_CR6","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/heartjnl-2020-316977","volume":"106","author":"WY Ding","year":"2020","unstructured":"Ding WY, Gupta D, Lip GYH. Atrial fibrillation and the prothrombotic state: revisiting Virchow\u2019s triad in 2020. Heart. 2020;106(19):1463\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2020-316977.","journal-title":"Heart"},{"issue":"19","key":"7736_CR7","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.3390\/jcm12196301","volume":"12","author":"P Ba\u0144ka","year":"2023","unstructured":"Ba\u0144ka P, Wybraniec M, Bochenek T, et al. Influence of aortic valve stenosis and wall shear stress on platelets function. J Clin Med. 2023;12(19):6301. https:\/\/doi.org\/10.3390\/jcm12196301.","journal-title":"J Clin Med"},{"issue":"1","key":"7736_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/eut263","volume":"16","author":"P Kirchhof","year":"2014","unstructured":"Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2013European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6\u201314. https:\/\/doi.org\/10.1093\/europace\/eut263.","journal-title":"Europace"},{"issue":"11","key":"7736_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"24","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;24(11):967\u201377. https:\/\/doi.org\/10.2147\/TCRM.S84210.","journal-title":"Ther Clin Risk Manag"},{"key":"7736_CR10","doi-asserted-by":"publisher","unstructured":"Lip GYH, Collet JP, Caterina R, et al. ESC Scientific Document Group. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLEACE). Europace. 2017;19(11):1757\u20131758. https:\/\/doi.org\/10.1093\/europace\/eux240.","DOI":"10.1093\/europace\/eux240"},{"issue":"Suppl A","key":"7736_CR11","doi-asserted-by":"publisher","first-page":"A19","DOI":"10.1093\/eurheartj\/suab151","volume":"24","author":"AC Fanaroff","year":"2022","unstructured":"Fanaroff AC, Vora AN, Lopes RD. Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. Eur Heart J Suppl. 2022;24(Suppl A):A19\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/suab151.","journal-title":"Eur Heart J Suppl"},{"issue":"13","key":"7736_CR12","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","volume":"138","author":"A Aimo","year":"2018","unstructured":"Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist oral anticoagulants for mechanical heart valves: is the door still open? Circulation. 2018;138(13):1356\u201365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035612.","journal-title":"Circulation"},{"issue":"12","key":"7736_CR13","doi-asserted-by":"publisher","first-page":"e006475","DOI":"10.1161\/JAHA.117.006475","volume":"6","author":"KL Thomas","year":"2017","unstructured":"Thomas KL, Jackson LR 2nd, Shrader P, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation). J Am Heart Assoc. 2017;6(12):e006475. https:\/\/doi.org\/10.1161\/JAHA.117.006475.","journal-title":"J Am Heart Assoc"},{"issue":"6 Suppl","key":"7736_CR14","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. https:\/\/doi.org\/10.1378\/chest.08-0670.","journal-title":"Chest"},{"issue":"2 Suppl","key":"7736_CR15","doi-asserted-by":"publisher","first-page":"e152S","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S. https:\/\/doi.org\/10.1378\/chest.11-2295.","journal-title":"Chest"},{"issue":"2","key":"7736_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, et al. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2024;124(2):135\u201348. https:\/\/doi.org\/10.1055\/s-0043-1769735.","journal-title":"Thromb Haemost"},{"issue":"3","key":"7736_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/jgs.15712","volume":"67","author":"L Eggebrecht","year":"2019","unstructured":"Eggebrecht L, Nagler M, G\u00f6bel S, et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc. 2019;67(3):463\u201370. https:\/\/doi.org\/10.1111\/jgs.15712.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"7736_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","volume":"131","author":"RG Hart","year":"1999","unstructured":"Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492\u2013501. https:\/\/doi.org\/10.7326\/0003-4819-131-7-199910050-00003.","journal-title":"Ann Intern Med"},{"issue":"2","key":"7736_CR19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/01.cir.89.2.635","volume":"89","author":"SC Cannegieter","year":"1994","unstructured":"Cannegieter SC, Rosendaal FR, Bri\u00ebt E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635\u201341. https:\/\/doi.org\/10.1161\/01.cir.89.2.635.","journal-title":"Circulation"},{"issue":"10","key":"7736_CR20","first-page":"e425","volume":"63","author":"D Gateman","year":"2017","unstructured":"Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician. 2017;63(10):e425\u201331.","journal-title":"Can Fam Physician"},{"issue":"13","key":"7736_CR21","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1300615.","journal-title":"N Engl J Med"},{"issue":"15","key":"7736_CR22","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","volume":"14","author":"D Capodanno","year":"2021","unstructured":"Capodanno D, Collet JP, Dangas G, et al. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(15):1688\u2013703. https:\/\/doi.org\/10.1016\/j.jcin.2021.06.020.","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"7736_CR23","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/cells11203214","volume":"11","author":"M Heestermans","year":"2022","unstructured":"Heestermans M, Poenou G, Hamzeh-Cognasse H, et al. A short history, their mechanism of action, pharmacology, and indications. Cells. 2022;11(20):3214. https:\/\/doi.org\/10.3390\/cells11203214.","journal-title":"Cells"},{"issue":"12","key":"7736_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"8","key":"7736_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","volume":"134","author":"MD Ezekowitz","year":"2016","unstructured":"Ezekowitz MD, Nagarakanti R, Noack H, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation. 2016;134(8):589\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020950.","journal-title":"Circulation"},{"issue":"10","key":"7736_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"13","key":"7736_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/heartjnl-2015-308120","volume":"102","author":"G Breithardt","year":"2016","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD, et al. ROCKET AF Steering Committee and Investigators. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102(13):1036\u201343. https:\/\/doi.org\/10.1136\/heartjnl-2015-308120.","journal-title":"Heart"},{"issue":"11","key":"7736_CR28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"8","key":"7736_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015;132(8):624\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014807.","journal-title":"Circulation"},{"issue":"22","key":"7736_CR30","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"11","key":"7736_CR31","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","volume":"69","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2017;69(11):1372\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.031.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"7736_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","volume":"135","author":"AP Carnicelli","year":"2017","unstructured":"Carnicelli AP, De Caterina R, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation. 2017;135(13):1273\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026714.","journal-title":"Circulation"},{"issue":"9","key":"7736_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","volume":"9","author":"A Zimerman","year":"2024","unstructured":"Zimerman A, Braunwald E, Steffel J, et al. Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 2024;9(9):817\u201325. https:\/\/doi.org\/10.1001\/jamacardio.2024.1793.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"7736_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. INVICTUS investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2209051.","journal-title":"N Engl J Med"},{"issue":"5","key":"7736_CR35","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10557-023-07470-z","volume":"38","author":"A Hammer","year":"2024","unstructured":"Hammer A, Niessner A, Sulzgruber P. Rivaroxaban in valvular atrial fibrillation - a critical appraisal of the INVICTUS trial. Cardiovasc Drugs Ther. 2024;38(5):1065\u20137. https:\/\/doi.org\/10.1007\/s10557-023-07470-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"7","key":"7736_CR36","doi-asserted-by":"publisher","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","volume":"2","author":"TY Wang","year":"2023","unstructured":"Wang TY, Svensson LG, Wen J, et al. Apixaban or warfarin in patients with an On-X mechanical aortic valve. NEJM Evid. 2023;2(7):EVIDoa2300067. https:\/\/doi.org\/10.1056\/EVIDoa2300067.","journal-title":"NEJM Evid"},{"issue":"22","key":"7736_CR37","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E, Silva PGM, et al. RIVER trial investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2029603.","journal-title":"N Engl J Med"},{"issue":"1","key":"7736_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","volume":"165","author":"CY Shim","year":"2023","unstructured":"Shim CY, Seo J, Kim YJ, et al. Explore the efficacy and safety of edoxaban in patients after heart valve repair or bioprosthetic valve replacement (ENAVLE) study group. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. 2023;165(1):58-67.e4. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.01.127.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"2","key":"7736_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, W\u00f6hrle J, et al. GALILEO investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1911425.","journal-title":"N Engl J Med"},{"issue":"2","key":"7736_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1911426","volume":"382","author":"O De Backer","year":"2020","unstructured":"De Backer O, Dangas GD, Jilaihawi H, et al. GALILEO-4D investigators. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1911426.","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"7736_CR41","doi-asserted-by":"publisher","first-page":"ehaa946.2623","DOI":"10.1093\/ehjci\/ehaa946.2623","volume":"41","author":"GM Froehlich","year":"2020","unstructured":"Froehlich GM, Falk V, Endres M, et al. Randomized clinical trial comparing a rivaroxaban-based with an antiplatelet-based strategy for cerebral embolization after TAVR (EARTH TAVR)-a magnetic resonance imaging substudy of the GALILEO trial. Eur Heart J. 2020;41(Supplement_2):ehaa946.2623. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.2623.","journal-title":"Eur Heart J"},{"issue":"9","key":"7736_CR42","doi-asserted-by":"publisher","first-page":"e011074","DOI":"10.1161\/CIRCINTERVENTIONS.121.011074","volume":"14","author":"GM Fr\u00f6hlich","year":"2021","unstructured":"Fr\u00f6hlich GM, Endres M, Falk V, et al. Evaluation of cerebral thromboembolism after transcatheter aortic valve replacement (EARTH TAVR): a serial magnetic resonance imaging evaluation as substudy of the GALILEO trial. Circ Cardiovasc Interv. 2021;14(9):e011074. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.121.011074.","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"7736_CR43","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. ENVISAGE-TAVI AF investigators. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2111016.","journal-title":"N Engl J Med"},{"key":"7736_CR44","doi-asserted-by":"publisher","unstructured":"Collet JP, Van Belle E, Thiele H et al. ATLANTIS investigators of the ACTION Group. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43(29):2783\u20132797.https:\/\/doi.org\/10.1093\/eurheartj\/ehac242  .","DOI":"10.1093\/eurheartj\/ehac242"},{"issue":"18","key":"7736_CR45","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.jcin.2022.07.014","volume":"15","author":"G Montalescot","year":"2022","unstructured":"Montalescot G, Redheuil A, Vincent F, et al. ATLANTIS investigators of the ACTION group. Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy. JACC Cardiovasc Interv. 2022;15(18):1794\u2013804. https:\/\/doi.org\/10.1016\/j.jcin.2022.07.014.","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"7736_CR46","doi-asserted-by":"publisher","first-page":"e031506","DOI":"10.1161\/JAHA.123.031506","volume":"13","author":"M Akao","year":"2024","unstructured":"Akao M, Yamashita T, Fukuzawa M, et al. Efficacy and safety of low-dose edoxaban by body weight in very elderly patients with atrial fibrillation: a subanalysis of the randomized ELDERCARE-AF trial. J Am Heart Assoc. 2024;13(3):e031506. https:\/\/doi.org\/10.1161\/JAHA.123.031506.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"7736_CR47","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T, et al. ELDERCARE-AF committees and investigators. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020;383(18):1735\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2012883.","journal-title":"N Engl J Med"},{"issue":"13","key":"7736_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/heartjnl-2017-311425","volume":"104","author":"B Iung","year":"2018","unstructured":"Iung B, Leenhardt A, Extramiana F. Management of atrial fibrillation in patients with rheumatic mitral stenosis. Heart. 2018;104(13):1062\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2017-311425.","journal-title":"Heart"},{"issue":"3","key":"7736_CR49","first-page":"501","volume":"13","author":"D Bluestein","year":"2004","unstructured":"Bluestein D, Yin W, Affeld K, et al. Flow-induced platelet activation in mechanical heart valves. J Heart Valve Dis. 2004;13(3):501\u20138.","journal-title":"J Heart Valve Dis"},{"issue":"4","key":"7736_CR50","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1055\/s-0037-1615261","volume":"44","author":"V Russo","year":"2018","unstructured":"Russo V, Attena E, Mazzone C, et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost. 2018;44(4):364\u20139. https:\/\/doi.org\/10.1055\/s-0037-1615261.","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"7736_CR51","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","volume":"41","author":"V Russo","year":"2019","unstructured":"Russo V, Carbone A, Attena E, et al. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019;41(12):2549\u201357. https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.008.","journal-title":"Clin Ther"},{"issue":"1","key":"7736_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/biomedicines11010131","volume":"11","author":"A Carbone","year":"2023","unstructured":"Carbone A, Bottino R, D\u2019Andrea A, et al. Direct oral anticoagulants for stroke prevention in special populations: beyond the clinical trials. Biomedicines. 2023;11(1):131. https:\/\/doi.org\/10.3390\/biomedicines11010131.","journal-title":"Biomedicines"},{"issue":"2","key":"7736_CR53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.33963\/KP.a2022.0051","volume":"80","author":"R Bottino","year":"2022","unstructured":"Bottino R, Carbone A, Liccardo B, Imbalzano E, D\u2019Andrea A, Russo V. Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves. Kardiol Pol. 2022;80(2):137\u201350. https:\/\/doi.org\/10.33963\/KP.a2022.0051.","journal-title":"Kardiol Pol"},{"issue":"15","key":"7736_CR54","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.3390\/jcm12154984","volume":"12","author":"T Langenaeken","year":"2023","unstructured":"Langenaeken T, Vanoppen A, Janssens F, et al. DOACs in the anticoagulation of mechanical valves: a systematic review and future perspectives. J Clin Med. 2023;12(15):4984. https:\/\/doi.org\/10.3390\/jcm12154984.","journal-title":"J Clin Med"},{"issue":"Suppl B","key":"7736_CR55","doi-asserted-by":"publisher","first-page":"B41","DOI":"10.1093\/eurheartjsupp\/suad065","volume":"25","author":"C Rochira","year":"2023","unstructured":"Rochira C, Capodanno D. DOACs and rheumatic valvulopathy: always a red light? Eur Heart J Suppl. 2023;25(Suppl B):B41\u20135. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad065.","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"7736_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/24748706.2020.1812779","volume":"4","author":"G Dangas","year":"2020","unstructured":"Dangas G, Chiarito M, O\u2019Gara P, et al. Bioprosthetic valve thrombosis: insights from transcatheter and surgical implants. Structural Heart. 2020;4(5):382\u20138. https:\/\/doi.org\/10.1080\/24748706.2020.1812779.","journal-title":"Structural Heart"},{"issue":"6","key":"7736_CR57","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, et al. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022;14(6):1120. https:\/\/doi.org\/10.3390\/pharmaceutics14061120.","journal-title":"Pharmaceutics"},{"issue":"10","key":"7736_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.rec.2024.02.011","volume":"77","author":"MJ Serna","year":"2024","unstructured":"Serna MJ, Rivera-Caravaca JM, L\u00f3pez-G\u00e1lvez R, et al. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients. Rev Esp Cardiol. 2024;77(10):835\u201342. https:\/\/doi.org\/10.1016\/j.rec.2024.02.011.","journal-title":"Rev Esp Cardiol"},{"issue":"12","key":"7736_CR59","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/jth.13857","volume":"15","author":"IH Jaffer","year":"2017","unstructured":"Jaffer IH, Chan N, Roberts R, et al. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. J Thromb Haemost. 2017;15(12):2377\u201387. https:\/\/doi.org\/10.1111\/jth.13857.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"7736_CR60","doi-asserted-by":"publisher","first-page":"e12528","DOI":"10.1002\/rth2.12528","volume":"5","author":"S Sukumar","year":"2021","unstructured":"Sukumar S, Cabero M, Tiu S, et al. Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: an observational study. Res Pract Thromb Haemost. 2021;5(4):e12528. https:\/\/doi.org\/10.1002\/rth2.12528.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"7736_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/hematology.2024000666","volume":"2024","author":"S Mithoowani","year":"2024","unstructured":"Mithoowani S, Siegal D. DOACs: role of anti-Xa and drug level monitoring. Hematol Am Soc Hematol Educ Program. 2024;2024(1):178\u201385. https:\/\/doi.org\/10.1182\/hematology.2024000666.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"21","key":"7736_CR62","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.3390\/jcm12216785","volume":"12","author":"N Riahi","year":"2023","unstructured":"Riahi N, Rozen L, Demulder A. Usefullness of heparin calibrated anti-Xa activity to assess anticoagulant activity of apixaban and rivaroxaban in emergency patients scheduled for acute interventions. J Clin Med. 2023;12(21):6785. https:\/\/doi.org\/10.3390\/jcm12216785.","journal-title":"J Clin Med"},{"key":"7736_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07573-1","author":"V Russo","year":"2024","unstructured":"Russo V, Caiazza E, Femine FCD, et al. Predictors of plasma levels of direct oral anticoagulants among patients with atrial fibrillation in need of elective cardiac procedures. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07573-1.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"7736_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/pharmacy11010034","volume":"11","author":"M Aldhaeefi","year":"2023","unstructured":"Aldhaeefi M, Badreldin HA, Alsuwayyid F, et al. Practical guide for anticoagulant and antiplatelet reversal in clinical practice. Pharmacy (Basel). 2023;11(1):34. https:\/\/doi.org\/10.3390\/pharmacy11010034.","journal-title":"Pharmacy (Basel)"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07736-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07736-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T22:02:06Z","timestamp":1773698526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07736-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7736"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07736-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"6 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}